PPA
SNDX icon

Parametric Portfolio Associates’s Syndax Pharmaceuticals SNDX Stock Holding History

Parametric Portfolio Associates’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$365K Sell
20,981
-6,845
-25% -$115K ﹤0.01% 3217
2021
Q4 		$609K Buy
27,826
+1,126
+4% +$20.8K ﹤0.01% 2988
2021
Q3 		$510K Sell
26,700
-4,589
-15% -$76.5K ﹤0.01% 3101
2021
Q2 		$537K Sell
31,289
-380
-1% -$6.96K ﹤0.01% 3058
2021
Q1 		$708K Buy
31,669
+10,723
+51% +$242K ﹤0.01% 3318
2020
Q4 		$466K Buy
20,946
+3,380
+19% +$70.1K ﹤0.01% 3414
2020
Q3 		$259K Sell
17,566
-4,120
-19% -$62.8K ﹤0.01% 3544
2020
Q2 		$321K Buy
21,686
+4,065
+23% +$61.9K ﹤0.01% 3447
2020
Q1 		$193K Sell
17,621
-2,106
-11% -$19.8K ﹤0.01% 3563
2019
Q4 		$173K Sell
19,727
-99
-0.5% -$727 ﹤0.01% 3773
2019
Q3 		$148K Buy
19,826
+1,512
+8% +$13.8K ﹤0.01% 3771
2019
Q2 		$171K Buy
18,314
+5,162
+39% +$37.6K ﹤0.01% 3767
2019
Q1 		$69K Buy
+13,152
New +$75K ﹤0.01% 3855
2017
Q4 		– Sell
-34,310
Closed -$401K – 3939
2017
Q3 		$401K Sell
34,310
-2,255
-6% -$27.6K ﹤0.01% 3545
2017
Q2 		$511K Buy
36,565
+13,911
+61% +$159K ﹤0.01% 3360
2017
Q1 		$311K Sell
22,654
-473
-2% -$4.91K ﹤0.01% 3414
2016
Q4 		$166K Sell
23,127
-464
-2% -$5.08K ﹤0.01% 3630
2016
Q3 		$358K Buy
23,591
+298
+1% +$3.92K ﹤0.01% 3340
2016
Q2 		$229K Buy
+23,293
New +$319K ﹤0.01% 3556

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Parametric Portfolio Associates's SNDX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Syndax Pharmaceuticals (SNDX) stake by 25% in Q1 2022, selling an estimated $115K and leaving 20,981 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #3217.

Parametric Portfolio Associates first reported a position in SNDX in Q2 2016 and has held it in 19 quarters since. The position peaked at $708K in Q1 2021. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Parametric Portfolio Associates held 20,981 shares of Syndax Pharmaceuticals worth $365K as of Q1 2022.
  • Parametric Portfolio Associates sold 6,845 Syndax Pharmaceuticals shares in Q1 2022, an estimated $115K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3217 holding.
  • Parametric Portfolio Associates first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 19 quarters since.
  • Parametric Portfolio Associates's Syndax Pharmaceuticals position peaked at $708K in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.